✦ LIBER ✦

A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial

✍ Scribed by Sean R. Duffy; Wolfgang Distler; Anthony Howell; Jack Cuzick; Michael Baum

Book ID: 113433940
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 261 KB
Volume: 200
Category: Article
ISSN: 1097-6868
DOI: 10.1016/j.ajog.2008.07.062

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A lower incidence of gynecologic adverse

A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial

✍ Vassilopoulou-Sellin, R. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 127 KB

P115 Fewer gynaecological adverse events

P115 Fewer gynaecological adverse events (AEs), gynaecological interventions, endometrial changes and abnormalities with anastrozole than with tamoxifen: findings from the ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) trial

✍ W. Distle 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 58 KB

0130 Initial adjuvant therapy with anast

0130 Initial adjuvant therapy with anastrozole - early- and late-event data from the arimidex, tamoxifen, alone or in combination (ATAC) trial in the hormone-responsive population

✍ A. Howell; J. Forbes; J. Cuzick 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 52 KB

Anastrozole alone or in combination with

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer : Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses

✍ The ATAC (Arimidex; Tamoxifen Alone or in Combination) Trialists' Group 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB 👁 2 views

## Abstract ## BACKGROUND The first analysis of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial (median follow‐up, 33 months) demonstrated that in adjuvant endocrine therapy for postmenopausal patients with early‐stage breast cancer, anastrozole was superior to tamoxifen in terms of d

Anastrozole is safer and may be more eff

Anastrozole is safer and may be more effective than tamoxifen in postmenopausal women with early-stage breast cancer: Abstracted from: Baum M, Buzdar A, Cuzick J, et al. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Cancer 2003;98:1802–10

✍ Hetty Carraway; Antonio C. Wolff 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 151 KB

Cost-effectiveness analysis of anastrozo

Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial

✍ Gershon Y. Locker; Robert Mansel; David Cella; Deborah Dobrez; Sonja Sorensen; S 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 267 KB